BACKGROUND: Semaphorin 7A (SEMA7A) is an immunomodulating protein implicated in lung and liver fibrosis. In autosomal-dominant polycystic kidney disease (ADPKD), the progressive expansion of renal cysts, inflammation, and subsequent renal fibrosis leads to end-stage renal disease (ESRD). SEMA7A may play a role in renal fibrosis and in ADPKD. METHODS: We evaluated Sema7a in a mouse model of renal fibrosis and determined the expression of SEMA7A in human ADPKD kidney. We analyzed SEMA7A expression on peripheral blood mononuclear cells (PBMCs), including CD45+ (leukocyte), CD14+(monocyte), CD4+ (T lymphocytes) and CD4+Foxp3+CD25+ [regulatory T lymphocytes (Tregs)] from 90 ADPKD patients (11 tolvaptan treated and 79 tolvaptan naïve), and 21 healthy volunteers, using a Fluorescence-Activated Cell Sorting (FACS). RESULTS: Sema7a is required for renal fibrosis. SEMA7A shows robust expression in ADPKD kidneys, localizing to cysts derived from distal tubules. SEMA7A is higher in circulating monocytes, but unchanged in CD4+ lymphocytes in ADPKD patients. The SEMA7A increase was detected early (stage 1 CKD) and seemed more prominent in patients with smaller kidneys (p = 0.09). Compared to tolvaptan-naïve ADPKD patients, those treated with tolvaptan showed reduced SEMA7A expression on monocytes, T lymphocytes, and Tregs, although the number of PBMCs was unchanged. After 1 month of tolvaptan treatment, SEMA7A expression on Tregs decreased. CONCLUSIONS: SEMA7A shows potential as both a therapeutic target in mammalian kidney fibrosis and as a marker of inflammation in ADPKD patients. SEMA7A expression was lower after tolvaptan treatment, which may reflect drug efficacy.
BACKGROUND:Semaphorin 7A (SEMA7A) is an immunomodulating protein implicated in lung and liver fibrosis. In autosomal-dominant polycystic kidney disease (ADPKD), the progressive expansion of renal cysts, inflammation, and subsequent renal fibrosis leads to end-stage renal disease (ESRD). SEMA7A may play a role in renal fibrosis and in ADPKD. METHODS: We evaluated Sema7a in a mouse model of renal fibrosis and determined the expression of SEMA7A in humanADPKD kidney. We analyzed SEMA7A expression on peripheral blood mononuclear cells (PBMCs), including CD45+ (leukocyte), CD14+(monocyte), CD4+ (T lymphocytes) and CD4+Foxp3+CD25+ [regulatory T lymphocytes (Tregs)] from 90 ADPKDpatients (11 tolvaptan treated and 79 tolvaptan naïve), and 21 healthy volunteers, using a Fluorescence-Activated Cell Sorting (FACS). RESULTS:Sema7a is required for renal fibrosis. SEMA7A shows robust expression in ADPKD kidneys, localizing to cysts derived from distal tubules. SEMA7A is higher in circulating monocytes, but unchanged in CD4+ lymphocytes in ADPKDpatients. The SEMA7A increase was detected early (stage 1 CKD) and seemed more prominent in patients with smaller kidneys (p = 0.09). Compared to tolvaptan-naïve ADPKDpatients, those treated with tolvaptan showed reduced SEMA7A expression on monocytes, T lymphocytes, and Tregs, although the number of PBMCs was unchanged. After 1 month of tolvaptan treatment, SEMA7A expression on Tregs decreased. CONCLUSIONS:SEMA7A shows potential as both a therapeutic target in mammaliankidney fibrosis and as a marker of inflammation in ADPKDpatients. SEMA7A expression was lower after tolvaptan treatment, which may reflect drug efficacy.
Authors: Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Ronald D Perrone; Ann Dandurand; John Ouyang; Frank S Czerwiec; Jaime D Blais Journal: Nephrol Dial Transplant Date: 2017-07-01 Impact factor: 5.992
Authors: A Yamada; K Kubo; T Takeshita; N Harashima; K Kawano; T Mine; K Sagawa; K Sugamura; K Itoh Journal: J Immunol Date: 1999-04-01 Impact factor: 5.422
Authors: Li Chen; Xia Zhou; Lucy X Fan; Ying Yao; Katherine I Swenson-Fields; Mihaela Gadjeva; Darren P Wallace; Dorien J M Peters; Alan Yu; Jared J Grantham; Xiaogang Li Journal: J Clin Invest Date: 2015-05-11 Impact factor: 14.808
Authors: M Mrug; J Zhou; Y Woo; X Cui; A J Szalai; J Novak; G A Churchill; L M Guay-Woodford Journal: Kidney Int Date: 2007-10-24 Impact factor: 10.612
Authors: York Pei; James Obaji; Annie Dupuis; Andrew D Paterson; Riccardo Magistroni; Elizabeth Dicks; Patrick Parfrey; Benvon Cramer; Eliecer Coto; Roser Torra; Jose L San Millan; Robert Gibson; Martijn Breuning; Dorien Peters; David Ravine Journal: J Am Soc Nephrol Date: 2008-10-22 Impact factor: 10.121
Authors: Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Ronald D Perrone; Gary Koch; John Ouyang; Robert D McQuade; Jaime D Blais; Frank S Czerwiec; Olga Sergeyeva Journal: N Engl J Med Date: 2017-11-04 Impact factor: 91.245
Authors: Jared J Grantham; Arlene B Chapman; Jaime Blais; Frank S Czerwiec; Olivier Devuyst; Ron T Gansevoort; Eiji Higashihara; Holly Krasa; Wen Zhou; John Ouyang; Ronald D Perrone; Vicente E Torres Journal: Nephrol Dial Transplant Date: 2017-06-01 Impact factor: 5.992
Authors: Ruijuan Gao; Xueyan Peng; Carrighan Perry; Huanxing Sun; Aglaia Ntokou; Changwan Ryu; Jose L Gomez; Benjamin C Reeves; Anjali Walia; Naftali Kaminski; Nir Neumark; Genta Ishikawa; Katharine E Black; Lida P Hariri; Meagan W Moore; Mridu Gulati; Robert J Homer; Daniel M Greif; Holger K Eltzschig; Erica L Herzog Journal: J Clin Invest Date: 2021-01-04 Impact factor: 14.808
Authors: Valeriia Y Vasileva; Regina F Sultanova; Anastasia V Sudarikova; Daria V Ilatovskaya Journal: Front Physiol Date: 2021-09-08 Impact factor: 4.566